Zoledronate In the Prevention of Paget's Disease: Long Term Extension
Launched by UNIVERSITY OF EDINBURGH · Feb 28, 2019
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
It is at present unclear whether intervention with bisphosphonates is of clinical benefit in early PDB. Although the ZiPP study is expected to provide information on whether ZA can favourably influence the development of bone lesions characteristic of early PDB as determined by radionuclide bone scan imaging, longer term follow up is required to determine if this will translate into clinical benefit. The extension study described here will provide new information on the natural history of PDB by follow up of people that took part in the ZIPP trial. Although the ZIPP-LTE study is an observat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject that participated in ZiPP
- • Participant willing and able to consent and comply with the study protocol.
- Exclusion Criteria:
- • Unable or unwilling to provide informed consent
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, England, United Kingdom
Siena, , Italy
Manchester, England, United Kingdom
Salamanca, , Spain
Dublin, , Ireland
Wrexham, Wales, United Kingdom
Turin, , Italy
Sydney, , Australia
Edinburgh, Scotland, United Kingdom
Geelong, , Australia
Nedlands, , Australia
Newcastle, , Australia
Toowoomba, , Australia
Brussels, , Belgium
Florence, , Italy
Auckland, , New Zealand
Christchurch, , New Zealand
Barcelona, , Spain
Bristol, England, United Kingdom
Liverpool, England, United Kingdom
London, England, United Kingdom
Patients applied
Trial Officials
Stuart Ralston, Prof
Principal Investigator
Univeristy of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials